[Human transfer factor. II. Clinical results with the large pool transfer factor].
21 patients with diseases due to immunological causes were treated 6 times at an interval of four weeks by administering 5 E TF or 1 E TF each per 10 kg of body weight. TF consisted of 5 different large pool TF charges of 420 to 822 buffy-coats of fresh stored whole blood. Clinical and immunological investigations as well as biochemical ones in the laboratory were made before and after treatment. Large pool TF is clinically effective in 9 from 18 patients and immunologically in 16 from 18 patients. There is a greater effect in immunodeficiencies than in autoimmune diseases. TF is not able to remove the defect for a long time. Repeated administrations are required. TF therapy may be regarded as a substitution therapy. At first, the intervals have to be chosen according to clinical parameters (recidive of the disease or crisis respectively). There is a good compatibility of TF. Side-effects could not be observed. The frequent immunological conversions after score evaluation indicate, however, that in comparison to the clinical appearance the course of the disease must be seen to be much more complex than it can be expressed by in vitro correlates of immunological responses. Statistically ensured correlations of single tests concerning the clinical course could also not be found. Large pool TF provides favourable conditions for controlled therapy trials in order to elucidate those findings of therapy which hitherto had been a subject of controversy (e.g. autoimmune diseases, tumours).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy*; D007223:Infant; D007273:Injections, Intramuscular; D008875:Middle Aged; D012397:Rosette Formation; D012882:Skin Tests; D014165:Transfer Factor / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*
D014165:Transfer Factor
Humaner Transfer-Faktor. II. Klinische Ergebnisse mit dem Grosspool-Transfer-Faktor.